A recent case report published in The Journal of Sexual Medicine details the experiences of two men who found relief from a rare, debilitating condition triggered by ejaculation. The patients, who suffered from severe flu-like and cognitive symptoms after orgasm, experienced major improvements after taking an antidepressant medication. These findings offer a potential therapeutic option for an illness that currently has no standard treatment.
Post-orgasmic illness syndrome is a medical condition characterized by physical and cognitive symptoms that emerge shortly after a person experiences an orgasm. People with this condition often report extreme fatigue, muscle weakness, feverishness, and difficulty concentrating. These symptoms typically last anywhere from two to seven days, frequently causing individuals to avoid sexual activity entirely.
The emotional toll of this condition can be severe. Men dealing with these symptoms often report low self-esteem, feelings of helplessness, and immense strain in their intimate relationships. Many patients internalize the blame for their sexual difficulties, believing that their physical or psychological makeup is fundamentally flawed.
The exact biological mechanisms behind this illness remain poorly understood. Some medical professionals suspect the condition stems from an autoimmune response, where the body mistakenly attacks its own seminal fluid. Other researchers propose that the syndrome is driven by an imbalance in the nervous system and hormones, specifically involving brain chemicals like serotonin and dopamine.
Because the root cause is still debated, doctors have struggled to find reliable treatments. Past attempts have included allergy medications, anti-inflammatory drugs, and even therapies designed to desensitize the immune system to semen. However, these interventions often yield inconsistent results, leaving many patients without relief.
Thalia Herder, a psychiatrist at the University Medical Center Utrecht in the Netherlands, and her colleagues authored the new report to explore an alternative treatment pathway. They wanted to investigate whether regulating specific chemical signals in the brain could alleviate the physical and mental exhaustion. The research team focused on the use of sertraline, a common medication known as a selective serotonin reuptake inhibitor.
This type of drug is typically prescribed for depression and anxiety, but it also alters how the brain handles stress responses and sexual function. By increasing the availability of serotonin between nerve cells, the medication might help stabilize the nervous system after the intense physical and emotional release of an orgasm. Herder and her team documented the clinical outcomes of two patients who received this treatment.
The first patient was a 28-year-old man who had experienced extreme fatigue, a general unwell feeling, nasal congestion, and “brain fog” after orgasm for his entire life. These symptoms reliably appeared within an hour of ejaculation and persisted for up to a week. The man had previously tried taking allergy pills and pain relievers, but neither provided any benefit.
During his clinical evaluation, doctors noted that he became highly irritable and struggled with mental clarity during these post-orgasmic episodes. He also revealed a long history of severe discomfort in social settings, leading the medical team to diagnose him with social anxiety disorder. To address both the social anxiety and the post-orgasmic symptoms, his doctors prescribed a daily dose of sertraline.
After three months of gradually increasing the dosage, the patient reported a substantial reduction in both his social anxiety and his post-orgasmic illness. The intensity of his physical fatigue and cognitive fog decreased, and the duration of his symptoms shortened. He did not experience any adverse side effects from the medication.
The second patient was a 29-year-old man who experienced profound fatigue, muscle pain, and a lingering sense of worthlessness after both partnered sex and masturbation. These issues had plagued him since he first became sexually active as a teenager. His post-orgasmic symptoms routinely impaired his performance at work, forcing him to plan his sexual activity around his professional schedule.
This patient also struggled with lifelong premature ejaculation, a condition that had not responded to physical exercises or numbing ointments. Because selective serotonin reuptake inhibitors are known to delay ejaculation, his doctors prescribed a daily dose of sertraline. Within one month of starting the medication, his time to ejaculation increased substantially.
Alongside the improvement in his sexual functioning, the man noticed a marked decline in his post-orgasmic muscle pain, weakness, and mood disturbances. The researchers noted that this therapeutic effect remained stable over a three-year observation period. Like the first patient, he experienced no notable negative side effects from the daily medication.
The researchers suggest that sertraline may work by calming the body’s neuroendocrine system. An orgasm involves a coordinated burst of autonomic and endocrine activity, which includes the release of various hormones and stress signals. In people with post-orgasmic illness syndrome, this system may become dysregulated, leading to a prolonged and exhausting stress response.
By blocking the reuptake of serotonin, sertraline helps quiet excessive stress-related signaling in the brain. The drug also mildly influences dopamine, a chemical tied to motivation and reward. Normalizing these pathways may prevent the intense drops in energy and mood that characterize the post-ejaculatory crash.
While these outcomes are highly encouraging, the researchers caution that a definitive cause-and-effect relationship cannot be established from just two patients. Case reports are observational accounts of individual medical treatments, meaning they lack the strict controls found in larger clinical trials. The statistical strength of these results was not significant, as the sample size is too small to draw broad mathematical conclusions.
It is possible that the medication only works for a specific subset of people. Patients whose symptoms are driven by nervous system imbalances or underlying anxiety might respond well, while those with primary immune system allergies might not. Other limitations include the lack of standardized symptom tracking and the presence of overlapping psychiatric conditions in both men.
Despite these drawbacks, case reports offer an essential starting point for medical discovery. They allow doctors to share novel observations and unexpected treatment successes that might otherwise go undocumented. By publishing these individual successes, researchers can generate new hypotheses and guide the design of larger, more rigorous studies.
Moving forward, the authors recommend that scientists conduct controlled clinical trials to better understand how selective serotonin reuptake inhibitors interact with this specific syndrome. Future research should aim to identify the exact biological markers that predict whether a patient will respond to this type of medication. Until then, the findings suggest that doctors should consider evaluating patients’ psychological and neurological profiles when searching for individualized treatments.
The study, “Postorgasmic illness syndrome (POIS) in two patients responding to sertraline: a case report,” was authored by Thalia Herder, Rikus Knegtering, Nynke Boonstra, and Kor Spoelstra.
